Abstract
Platinum-based drugs are very useful in cancer therapy but are associated with neurotoxicity in the clinic. To investigate the mechanism of neurotoxicity, dorsal root ganglia of rats treated with various platinum drugs were studied. Cell body, nuclear and nucleolar dimensions of dorsal root ganglia sensory nerve cells were measured to determine morphological toxicity. Sensory nerve conduction velocity was measured to determine functional toxicity. After a single dose of oxaliplatin (10 mg kg–1), no significant change in nuclear and cell body diameter was seen but decreased nucleolar size was apparent within a few hours of treatment. Changes in nucleolar size were maximal at 24 hours, recovered very slowly and showed a non-linear dependence on oxaliplatin dose (r2= 0.99). Functional toxicity was delayed in onset until 14 days after a single dose of oxaliplatin but eventually recovered 3 months after treatment. Multiple doses of cisplatin, carboplatin, oxaliplatin, R, R -ormaplatin and S, S -ormaplatin were also associated with time-dependent reduction in nucleolar size. A linear correlation was obtained between the rate of change in nucleolar size during multiple dose treatment with the series of platinum drugs and the time taken for the development of altered sensory nerve conduction velocity (r2= 0.86;P< 0.024). Damage to the nucleolus of ganglionic sensory neurons is therefore linked to the neurotoxicity of platinum-based drugs, possibly through mechanisms resulting in the inhibition of rRNA synthesis. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Brasch K (1990) Drug and metabolite-induced perturbations in nuclear structure and function: a review. Biochem Cell Biol 68: 408–426
Cavaletti G, Tredici G, Marmiroli P, Petruccioloi MG, Barajon I and Fabbrica D (1992) Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats. Acta Neuropathol 84: 364–371
Cavaletti G, Fabbrica D, Minoia C, Frattola L and Tredici G (1998) Carboplatin toxic effects on the peripheral nervous system of the rat. Ann Oncol 9: 443–447
Cece R, Petruccioli MG, Cavaletti G, Barajon I and Tredici G (1995a) An ultrastructural study of neuronal changes in dorsal root ganglia (DRG) of rats after chronic cisplatin administrations. Histol Histopathol 10: 837–845
Cece R, Petruccioli MG, Pizzini G, Cavaletti G and Tredici G (1995b) Ultrastructural aspects of DRG satellite cell involvement in experimental cisplatin neuronopathy. Submicrosc Cytol Pathol 27: 417–425
Coggeshall RE, La Forte R and Klen CM (1990) Calibration of methods for determining numbers of dorsal root ganglia cells. J Neurosci Meth 35: 187–194
Einhorn LH (1997) Testicular Cancer: An Oncological success Story. Clin Cancer Res 3: 2630–2632
Extra J-M, Marty M, Brienza S and Misset J-L (1998) Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 25(Suppl 5: 13–22
Fink D and Howell SB (2000) How does cisplatin kill cells?. Platinum-based drugs in cancer therapy, Kelland LR, Farrell N (eds.) pp 149–167. Humana Press: Totowa NJ
Gregg RW, Molepa JM, Monpetit VJA, Mikeal NZ, Redmond D, Gadia M and Stewart DJ (1992) Cisplatin neurotoxicity: the relationships between dosage, time and platinum concentration in neurological tissues, and morphological evidence of toxicity. J Clin Oncol 10: 795–803
Harder HC and Rosenberg B (1970) Inhibitory effects of antitumor platinum compounds on DNA, RNA and protein synthesis in mammalian cells in vitro. Int J Cancer 6: 207–216
Holmes J, Stanko J, Varchenko M, Ding H, Madden VJ, Bagnell CR, Wyrick SD and Chaney SG (1998) Comparative neurotoxicity of oxaliplatin, cisplatin and ormaplatin in a Wistar rat model. Toxicol Sci 46: 342–351
Ivanov AI, Christodoulou J, Parkinson JA, Barnham KJ, Tucker A, Woodrow J and Sadler PJ (1998) Cisplatin binding sites on human albumin. J Biol Chem 273: 14721–14730
Jamieson ER and Lippard SJ (1999) Structure, recognition and processing of cisplatin-DNA adducts. Chem Rev 99: 2467–2498
Jones TW, Chopra S, Kaufman JS, Flamenbaum W and Trump BF (1985) cis -diamminedichloroplatinum(II)-induced acute renal failure in the rat. Lab Invest 52: 363–374
Jordon P and Carmo-Fonseca M (1998) Cisplatin inhibits synthesis of ribosomal RNA. in vivo. Nucleic Acids Res 26: 2831–2836
Lehane D, Winston A, Gray R and Daskal Y (1979) The effect of diuretic pre-treatment on clinical, morphological and ultrastructural cis -platinum induced nephrotoxicity. Int J Radiat Oncol 5: 1393–1399
Leibbrandt MEI, Wolfgang GHI, Metz AL, Ozobia AA and Haskins JR (1995) Critical subcellular targets of cisplatin and related platinum analogs in rat renal proximal tubule cells. Kidney Int 48: 761–770
Lemaire M-A, Schwartz A, Rahmount AR and Leng M (1991) Interstrand cross-links are preferentially formed at the d(GC) sites in the reaction between cis-diamminedichloroplatinum(II) and DNA. Proc Natl Acad Sci USA 88: 1982–1985
McKeage MJ (2000) Clinical toxicology of platinum-based cancer chemotherapeutic agents. Platinum-based drugs in cancer therapy, Kelland LR, Farrell N (eds.) pp 251–275, Humana Press: Totowa NJ
McKeage MJ, Boxall F, Jones M and Harrap KR (1994) Lack of neurotoxicity of oral bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in comparison to cisplatin and tetraplatin in the rat. Cancer Res 54: 629–631
Misset J-L (1998) Oxaliplatin in practice. Brit J Cancer 77 (Suppl 4): 4–7
Muller LJ, Gerritsen Van Der Hoop R, Moorer-Van Delft CM, Gispen WH and Roubos EW (1990) Morphological and electrophysiological study of the effects of cisplatin and ORG2766 on rat spinal ganglia neurons. Cancer Res 50: 2437–2442
O’Rourke TJ, Weiss GR, New P, Burris HA, Rodriguez G, Eckhart J, Hardy J, Kuhn JG, Fields S and Clark GM (1994) Phase I clinical trial of ormaplatin (tetraplatin, NSC363812). Anti-Cancer Drug 5: 520–526
Ozols RF (2000) Optimum chemotherapy for ovarian cancer. Int J Gynecol Cancer 10(Suppl 1): 33–37
Ozols RF, Corden BJ, Jacob J, Wesley MN, Ostchega Y and Young RC (1984) High-dose cisplatin in hypertonic saline. Ann Intern Med 100: 19–24
Poirier MC, Reed E, Litterest CL and Gupta-Burt S (1992) Persistence of platinum-amine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients. Cancer Res 52: 149–153
Schilder RJ, La Creta FP, Perez RP, Johnson SW, Brennan JM, Rogatko A, Nash S, McAleer C, Hamilton TC, Rody D, Young RC, Ozol RF and O’Dwyer PJ (1994) Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC363812) administered on a day 1 and 8 schedule. Cancer Res 54: 709–717
Schwartz JH (1991) The Cytology of Neurons. Principles of Neural Science (3rd Ed.), Kandel ER, Schwartz JH, Jessell TM (eds.) pps 37–48, Prentice-Hall International Ltd: London
Screnci D, Er HM, Hambley TW, Galettis P, Brouwer W and McKeage MJ (1997) Stereoselective peripheral sensory neurotoxicity of diaminocyclohexane platinum enantiomers related to ormaplatin and oxaliplatin. Brit J Cancer 76: 502–510
Screnci D, McKeage MJ, Galettis P, Hambley TW, Palmer BD and Baguley BC (2000) Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs. Brit J Cancer 82: 966–972
Shaw PJ and Jordon EG (1995) The Nucleolus. Annu Rev Cell Dev Bi 11: 93–121
Sorenson CM, Barry MA and Eastman A (1992) Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer 182: 749–755
Stacchiotti A, Rezzani R, Rodella L and Ventura RG (1995) Lysosomal changes in rat spinal ganglia neurons after prolonged treatment with cisplatin. Acta Anat 153: 236–242
Thomas GM (1999) Improved treatment for cervical cancer-concurrent chemotherapy and radiotherapy. New Engl J Med 340: 1198–1199
Thompson SW, Davis LE, Kornfeld M, Hilger DR and Standefer JC (1984) Cisplatin neurotoxicity; clinical, electrophysiologic, morphologic and toxicologic studies. Cancer 54: 1269–1275
Tomiwa K, Nolan C and Cavanagh JB (1986) The effects of cisplatin on rat spinal ganglia: a study by light and electron microscopy and morphometry. Acta Neuropathol 69: 295–308
Treiber DK, Zhai X, Jantzen H-M and Essigmann JM (1994) Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor). P Natl Acad Sci USA 91: 5672–5676
Vichi P, Coin F, Renaud J-P, Vermeulen W, Hoeijmakers JHJ, Moras D and Egly J-M (1997) Cisplatin- and UV-damaged DNA lure the basal transcription factor TFIID/TBP. EMBO J 16: 7444–7456
Zhai X, Beckmann H, Jantzen H-M and Essigmann JM (1998) Cisplatin-DNA adducts inhibit Ribosomal RNA synthesis by high-jacking the transcription factor human upstream binding factor. Biochemistry-US 37: 16307–16315
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
McKeage, M., Hsu, T., Screnci, D. et al. Nucleolar damage correlates with neurotoxicity induced by different platinum drugs. Br J Cancer 85, 1219–1225 (2001). https://doi.org/10.1054/bjoc.2001.2024
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.2024
Keywords
This article is cited by
-
Melittin, a honeybee venom derived peptide for the treatment of chemotherapy-induced peripheral neuropathy
Medical Oncology (2021)
-
Neu-horizons: neuroprotection and therapeutic use of riluzole for the prevention of oxaliplatin-induced neuropathy—a randomised controlled trial
Supportive Care in Cancer (2021)
-
Pharmacokinetic and toxicodynamic evaluation of oxaliplatin-induced neuropathy and hematological toxicity in rats
Cancer Chemotherapy and Pharmacology (2018)
-
Nucleolar control of p53: a cellular Achilles’ heel and a target for cancer therapy
Cellular and Molecular Life Sciences (2014)
-
Ganglioside-monosialic acid (GM1) prevents oxaliplatin-induced peripheral neurotoxicity in patients with gastrointestinal tumors
World Journal of Surgical Oncology (2013)
